Novavax has entered into Amendment #5 to its Advanced Purchase Agreement with the Commonwealth of Australia on December 12, 2024. The amendment acknowledges the cancellation of certain COVID-19 vaccine deliveries scheduled between Q4 2023 and Q4 2025, with approximately $31 million in advanced payments being credited against outstanding and future deliveries of about 3 million doses.The agreement includes an updated delivery schedule extending through 2029 for potential COVID-19 vaccine or future variant vaccine deliveries. The Commonwealth retains rights to various remedies, including credit return, dose cancellation, or agreement termination if Novavax fails to meet delivery commitments or obtain regulatory approval for variant vaccines.Additional provisions grant the Commonwealth the right to cancel doses if Novavax fails to provide timely notification of commercialization plan changes, ensuring greater transparency and accountability in the partnership.

Novavax has entered into Amendment #5 to its Advanced Purchase Agreement with the Commonwealth of Australia on December 12, 2024. The amendment acknowledges the cancellation of certain COVID-19 vaccine deliveries scheduled between Q4 2023 and Q4 2025, with approximately $31 million in advanced payments being credited against outstanding and future deliveries of about 3 million doses.The agreement includes an updated delivery schedule extending through 2029 for potential COVID-19 vaccine or future variant vaccine deliveries. The Commonwealth retains rights to various remedies, including credit return, dose cancellation, or agreement termination if Novavax fails to meet delivery commitments or obtain regulatory approval for variant vaccines.Additional provisions grant the Commonwealth the right to cancel doses if Novavax fails to provide timely notification of commercialization plan changes, ensuring greater transparency and accountability in the partnership.